stockrowLivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.89%
- EPS
- +27.0%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) EV/FCF
As of 6 November 2026, LivaNova PLC (LIVN) trades at a EV/FCF of 35.4×. Over the past ten years it has ranged from −333× (October 2015) to 625× (June 2021); the current reading is higher than 37% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 17.5× | (4.02%) |
| FY2024 | 18.2× | (74.87%) |
| FY2023 | 72.5× | (2.49%) |
| FY2022 | 74.3× | 22.89% |
| FY2021 | 60.5× | — |
| FY2020 | −30.7× | — |
| FY2019 | −32.9× | — |
| FY2018 | 47.7× | (28.65%) |
| FY2017 | 66.8× | 33.43% |
| FY2016 | 50.1× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 29.7× | 5.25% |
| Jun 2026 | 28.2× | 44.43% |
| Mar 2026 | 19.5× | 11.82% |
| Dec 2025 | 17.5× | 24.11% |
| 45 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| HAE Haemonetics Corporation compare | 20.9× |
| BIO Bio-Rad Laboratories, Inc. compare | 28.8× |
| LIVN LivaNova PLC | 36.0× |
| BRKR Bruker Corporation compare | 38.8× |
| TXG 10x Genomics compare | 58.9× |
| NEOG Neogen Corporation compare | 63.4× |
| ITGR Integer Holdings Corporation compare | 68.9× |
| AXGN AxoGen, Inc. compare | 118× |
| IRTC iRhythm Holdings, Inc. compare | 598× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement